Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

The "Biopharmaceutical Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.The Global Biopharmaceutical ...

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk board and Lars Fruergaard Jorgensen have jointly concluded that ...

Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight ...

Eli Lilly and Company ( NYSE: LLY) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Lucas Montarce - CFO Mike Czapar - SVP, IR ...

The stock market experienced quite a bit of volatility during President Donald Trump's first 100 days in office.

Have you assessed how the international operations of Eli Lilly (LLY) performed in the quarter ended March 2025? For this drugmaker, possessing an expansive global footprint, parsing the trends of ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

The Business Research Company’s Huntington's Disease Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 ...